DB:51S

Stock Analysis Report

Executive Summary

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.


Snowflake Analysis

Exceptional growth potential with adequate balance sheet.

Share Price & News

How has Cynata Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 51S's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

18.2%

51S

11.7%

DE Biotechs

9.9%

DE Market


1 Year Return

-58.1%

51S

-8.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: 51S underperformed the German Biotechs industry which returned -8.1% over the past year.

Return vs Market: 51S underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

51SIndustryMarket
7 Day18.2%11.7%9.9%
30 Day-38.0%-5.9%-16.6%
90 Day-47.2%-22.6%-24.8%
1 Year-58.1%-58.1%-7.9%-8.1%-15.0%-17.5%
3 Year3.7%3.7%16.6%15.4%-17.4%-24.5%
5 Yearn/a-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is Cynata Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cynata Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 51S (€0.34) is trading below our estimate of fair value (€7.23)

Significantly Below Fair Value: 51S is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 51S is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 51S is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 51S's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 51S is overvalued based on its PB Ratio (7.6x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Cynata Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

106.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 51S is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: 51S is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 51S's is expected to become profitable in the next 3 years.

Revenue vs Market: 51S's revenue (65.6% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: 51S's revenue (65.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 51S's Return on Equity is forecast to be high in 3 years time (35.2%)


Next Steps

Past Performance

How has Cynata Therapeutics performed over the past 5 years?

-17.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 51S is currently unprofitable.

Growing Profit Margin: 51S is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 51S is unprofitable, and losses have increased over the past 5 years at a rate of -17.2% per year.

Accelerating Growth: Unable to compare 51S's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 51S is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 51S has a negative Return on Equity (-82.59%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cynata Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 51S's short term assets (A$6.2M) exceed its short term liabilities (A$1.1M).

Long Term Liabilities: 51S has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 51S is debt free.

Reducing Debt: 51S has no debt compared to 5 years ago when its debt to equity ratio was 0%.


Balance Sheet

Inventory Level: 51S has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 51S's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 51S has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 51S has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cynata Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 51S's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 51S's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 51S's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 51S's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 51S's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.6yrs

Average board tenure


CEO

Ross MacDonald (61yo)

no data

Tenure

AU$476,917

Compensation

Dr. Ross Alexander MacDonald, Ph.D. serves as Member of Investment Committee at Uniseed Pty Limited and also serves as the Chief Executive Officer and Managing Director at Cynata Therapeutics Limited (form ...


CEO Compensation Analysis

Compensation vs Market: Ross's total compensation ($USD293.76K) is below average for companies of similar size in the German market ($USD431.45K).

Compensation vs Earnings: Ross's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Ross MacDonald
MD, CEO & Executive Directorno dataAU$476.92k2.49% A$1.0m
Peter Webse
Company Secretary & Non-Executive Director7.83yrsAU$100.42k0.33% A$137.0k
Geoffrey Edward Brooke
Independent Non-Executive Director0.83yrAU$52.27kno data
Paul Wotton
Non-Executive Chairman3yrsAU$172.17k0.17% A$70.7k
Stewart Washer
Non-Executive Director6.58yrsAU$50.42k2.45% A$1.0m
Igor Slukvin
Member of Scientific Advisory Boardno datano datano data

6.6yrs

Average Tenure

59yo

Average Age

Experienced Board: 51S's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.4%.


Top Shareholders

Company Information

Cynata Therapeutics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cynata Therapeutics Limited
  • Ticker: 51S
  • Exchange: DB
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$74.173m
  • Listing Market Cap: AU$41.411m
  • Shares outstanding: 103.02m
  • Website: https://www.cynata.com

Location

  • Cynata Therapeutics Limited
  • 62 Lygon Street
  • Level 3
  • Carlton
  • Victoria
  • 3053
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYPASX (Australian Securities Exchange)YesOrdinary SharesAUAUDDec 2007
CYPCHIA (Chi-X Australia)YesOrdinary SharesAUAUDDec 2007
CYYN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2007
51SDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2007

Biography

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 00:02
End of Day Share Price2020/03/30 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.